CA2797121C - Anti-glucosaminidase passive immunization for staphylococcus aureus infections - Google Patents

Anti-glucosaminidase passive immunization for staphylococcus aureus infections Download PDF

Info

Publication number
CA2797121C
CA2797121C CA2797121A CA2797121A CA2797121C CA 2797121 C CA2797121 C CA 2797121C CA 2797121 A CA2797121 A CA 2797121A CA 2797121 A CA2797121 A CA 2797121A CA 2797121 C CA2797121 C CA 2797121C
Authority
CA
Canada
Prior art keywords
monoclonal antibody
antigen binding
binding portion
pharmaceutical composition
aureus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2797121A
Other languages
English (en)
French (fr)
Other versions
CA2797121A1 (en
Inventor
Edward M. Schwarz
Mark A. Sullivan
John L. Daiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of CA2797121A1 publication Critical patent/CA2797121A1/en
Application granted granted Critical
Publication of CA2797121C publication Critical patent/CA2797121C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/28—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2797121A 2010-05-03 2011-05-03 Anti-glucosaminidase passive immunization for staphylococcus aureus infections Active CA2797121C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33056810P 2010-05-03 2010-05-03
US61/330,568 2010-05-03
PCT/US2011/035033 WO2011140114A2 (en) 2010-05-03 2011-05-03 Anti-glucosaminidase passive immunization for staphylococcus aureus infections

Publications (2)

Publication Number Publication Date
CA2797121A1 CA2797121A1 (en) 2011-11-10
CA2797121C true CA2797121C (en) 2020-07-14

Family

ID=44904432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2797121A Active CA2797121C (en) 2010-05-03 2011-05-03 Anti-glucosaminidase passive immunization for staphylococcus aureus infections

Country Status (7)

Country Link
US (4) US9737601B2 (enExample)
EP (2) EP2566891B1 (enExample)
JP (3) JP6038777B2 (enExample)
AU (1) AU2011248209B2 (enExample)
CA (1) CA2797121C (enExample)
ES (1) ES2606017T3 (enExample)
WO (1) WO2011140114A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566891B1 (en) 2010-05-03 2016-11-02 University Of Rochester Anti-glucosaminidase passive immunization for staphylococcus aureus infections
AU2015224393B2 (en) * 2011-11-02 2016-12-15 University Of Rochester Anti-glucosaminidase passive immunization for staphylococcus aureus infections
CA2853943C (en) 2011-11-02 2015-12-08 University Of Rochester Anti-glucosaminidase passive immunization for staphylococcus aureus infections
WO2014143886A2 (en) * 2013-03-15 2014-09-18 Edimer Pharmaceuticals, Inc. Anti-ectodysplasin antibodies
ES2754209T3 (es) 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
JP2019509759A (ja) 2016-01-14 2019-04-11 ビーピーエス バイオサイエンス、インク．Ｂｐｓ Ｂｉｏｓｃｉｅｎｃｅ， Ｉｎｃ． 抗ｐｄ−１抗体及びその使用
KR20190129859A (ko) * 2017-02-10 2019-11-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-d 인자 항체 및 그의 용도
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CA3204730A1 (en) * 2021-01-15 2022-07-21 Gowrishankar MUTHUKRISHNAN Staphylococcus aureus antigen-based nucleic acid vaccines
WO2022174009A1 (en) * 2021-02-12 2022-08-18 Telephus Biosciences, Llc Antibodies that bind glucosaminidase and uses thereof
WO2025260048A2 (en) * 2024-06-14 2025-12-18 Qilu Puget Sound Biotherapeutics Corporation Anti-il33 and anti-tslp antibodies, and mixtures

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6228619B1 (en) 1996-02-20 2001-05-08 Smithkline Beecham Corporation Glucosaminidase
WO2009137677A2 (en) 2008-05-07 2009-11-12 Innovative Biosensors, Inc. Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
WO2010028013A2 (en) 2008-09-02 2010-03-11 University Of Maryland, Baltimore In vivo biofilm infection diagnosis and treatment
US8318180B2 (en) * 2008-09-30 2012-11-27 University Of Maryland, Baltimore Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens
EP2566891B1 (en) 2010-05-03 2016-11-02 University Of Rochester Anti-glucosaminidase passive immunization for staphylococcus aureus infections

Also Published As

Publication number Publication date
JP2018027974A (ja) 2018-02-22
JP6227092B2 (ja) 2017-11-08
JP6580649B2 (ja) 2019-09-25
JP2017105756A (ja) 2017-06-15
JP6038777B2 (ja) 2016-12-07
CA2797121A1 (en) 2011-11-10
EP2566891A2 (en) 2013-03-13
EP3150631A1 (en) 2017-04-05
US11065333B2 (en) 2021-07-20
US9737601B2 (en) 2017-08-22
WO2011140114A2 (en) 2011-11-10
US20180043021A1 (en) 2018-02-15
US10179170B2 (en) 2019-01-15
ES2606017T3 (es) 2017-03-17
US10653775B2 (en) 2020-05-19
EP2566891B1 (en) 2016-11-02
AU2011248209B2 (en) 2016-03-17
JP2013533210A (ja) 2013-08-22
US20200330597A1 (en) 2020-10-22
WO2011140114A3 (en) 2013-05-30
US20130110249A1 (en) 2013-05-02
EP2566891A4 (en) 2014-05-28
EP3150631C0 (en) 2023-08-30
EP3150631B1 (en) 2023-08-30
US20190314501A1 (en) 2019-10-17
AU2011248209A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
US11065333B2 (en) Anti-glucosaminidase passive immunization for Staphylococcus aureus infections
US10577431B2 (en) Passive immunization for Staphylococcus infections
US10112986B2 (en) Anti-glucosaminidase passive immunization for Staphylococcus aureus infections
AU2017201748B2 (en) Anti-glucosaminidase passive immunization for staphylococcus aureus infections
HK1236211A1 (en) Anti-glucosaminidase passive immunization for staphylococcus aureus infections
HK1236211B (en) Anti-glucosaminidase passive immunization for staphylococcus aureus infections

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160429

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425